In concrete, the Biotechnology Laboratory team at the University Hospital (University of Navarra), in close collaboration with the Pharmacogenomics laboratory at the Centre for Applied Medical Research (CIMA) of the same University, undertook these analyses predictive of responses to pharmaceutical drugs in patients with cancer of the lung, the colon and certain types of sarcoma.
Research into the mutations of a gene known as EGFR that can be found altered in lung cancer may help to determine the response of a new group of pharmaceutical – the tyrosine quinase inhibitors of the epidermic growth factor receptor. Also, the presence of genetic changes in specific fragments of PDGFR-alfa genes as well a sin the c-kit gene can pinpoint which treatment is likely to be more efficacious in certain gastrointestinal sarcomas. In this respect, the Department of Oncology at the University Hospital (University of Navarra) and the Centre for Applied Medical Research (CIMA) of the same University are collaborating in the identification of these genetic changes based on the study of the tumour prior to the application of treatment in the patient.
We are currently analysing genetic changes which will help us define the parameters needed to interpret what the best set of pharmaceutical drugs might be to act on certain tumours, particularly cancers of the lung, of the colon and sarcomas.
DIn this way, which patients best respond to a specific treatment can be identified. At the same time, we manage to know the toxicity profile that may occur using these medicinal drugs.
The procedure consists of a genetic analysis of a blood sample or of the cancerous tissue where the existence of certain mutations or polymorphisms are observed and enable us to predict what drugs are the most suitable for that particular patient. The analysis provides us with information about the most effective therapeutic option against the tumour, as well as what the potential side-effects are of this treatment on the patient. In this way a better therapeutic selection and individualisation for each patient is achieved.
The analysis of certain genetic variants called polymorphisms help to predict an increased toxicity risk due to treatment with certain antineoplasic pharmaceuticals. Providing the most suitable drug to each patient will mean reducing the symptoms of the toxicity - fatigue, digestive indisposition, cutaneous reaction, diarrhoea, vomiting, as well as alterations in the liver and kidney. In this way the patient will have a better quality of life.
A number of research projects undertaken by different teams have confirmed the use of these markers for response and toxicity and their role in drawing up more individualised therapeutic plan.
Irati Kortabitarte | alfa
Zebrafish's near 360 degree UV-vision knocks stripes off Google Street View
22.06.2018 | University of Sussex
New cellular pathway helps explain how inflammation leads to artery disease
22.06.2018 | Cedars-Sinai Medical Center
In a recent publication in the renowned journal Optica, scientists of Leibniz-Institute of Photonic Technology (Leibniz IPHT) in Jena showed that they can accurately control the optical properties of liquid-core fiber lasers and therefore their spectral band width by temperature and pressure tuning.
Already last year, the researchers provided experimental proof of a new dynamic of hybrid solitons– temporally and spectrally stationary light waves resulting...
Scientists from the University of Freiburg and the University of Basel identified a master regulator for bone regeneration. Prasad Shastri, Professor of...
Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.
Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...
The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.
Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.
An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.
Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...
13.06.2018 | Event News
08.06.2018 | Event News
05.06.2018 | Event News
22.06.2018 | Materials Sciences
22.06.2018 | Earth Sciences
22.06.2018 | Life Sciences